Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.
Chen EY, Kardosh A, Nabavizadeh N, Foster B, Mayo SC, Billingsley KG, Gilbert EW, Lanciault C, Grossberg A, Bensch KG, Maynard E, Anderson EC, Sheppard BC, Thomas CR Jr, Lopez CD, Vaccaro GM; OHSU Gastrointestinal Cancer Disease Group.
Chen EY, et al.
Cancer Med. 2023 Jun;12(12):12986-12995. doi: 10.1002/cam4.5971. Epub 2023 May 3.
Cancer Med. 2023.
PMID: 37132281
Free PMC article.
Clinical Trial.
METHODS: A single-arm, open-label phase 2 trial (NCT02427841) enrolled patients with pancreatic adenocarcinoma deemed to be borderline resectable or clinically node-positive from March 17, 2016 to October 5, 2019. Patients received preoperative gemcitabine 1000 mg/m(2) and …
METHODS: A single-arm, open-label phase 2 trial (NCT02427841) enrolled patients with pancreatic adenocarcinoma deemed to be borderline resec …